Optimal treatment of early stage HER2‐positive breast cancer
Author:
Affiliation:
1. Department of Medical OncologyInstitut Catala d’Oncologia‐H.U.Bellvitge‐IDIBELL L´Hospitalet‐Barcelona Spain
2. Department of Medical OncologyDana‐Farber Cancer Institute Boston Massachusetts
Funder
NIH Clinical Center
Mayo Foundation for Medical Education and Research
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31657
Reference66 articles.
1. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
2. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
3. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
4. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
5. Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Cited by 51 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review;Medicine;2024-06-14
2. Identification of Patients with Early HR+ HER2− Breast Cancer at High Risk of Recurrence;Geburtshilfe und Frauenheilkunde;2024-02
3. Prognostic Factors and Survival Outcomes of Patients With Early HER2+ Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study;Clinical Breast Cancer;2023-12
4. Current Management and Future Perspectives in Metastatic HER2-Positive Breast Cancer;Seminars in Oncology Nursing;2023-12
5. Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper;Clinical Breast Cancer;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3